Skip to main content
China Shineway Pharmaceutical Group Limited logo

China Shineway Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 2877 ISIN · KYG2110P1000 LEI · 5299001VVE1YDGPXXR74 HKEX Manufacturing
Open in API
Filings indexed 15 across all filing types
Latest filing 2026-05-07 Earnings Release
Country KY Cayman Islands
Listing HKEX 2877

About China Shineway Pharmaceutical Group Limited

http://www.shineway.com.hk

China Shineway Pharmaceutical Group Limited is engaged in the research, development, manufacturing, and distribution of modern Chinese medicines (MCMs). The company specializes in producing high-quality dosage forms, including modern Chinese injections, soft capsules, and granules, as well as TCM Formula Granules. Its diverse product portfolio targets various therapeutic areas, particularly cardiovascular health. The Group maintains control over the entire value chain, encompassing raw material cultivation through to final distribution. Focusing on innovation in the MCM sector, the company primarily serves the pharmaceutical market within the People's Republic of China.

Recent filings

Filing Released Lang Actions
TURNOVER FOR THE FIRST QUARTER OF 2026
Earnings Release Classification · 95% confidence The document is an announcement from China Shineway Pharmaceutical Group Limited regarding the turnover for the first quarter of 2026. It provides specific financial figures for the quarter ended 31 March 2026 based on management accounts that have not been audited. The content is a brief update on quarterly financial performance, focusing on turnover by product category, without detailed financial statements or comprehensive analysis. The document length is short (2159 characters) and it is not a full quarterly report but rather a summary announcement of quarterly turnover. This fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly financial results with key highlights only.
2026-05-07 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a monthly return report submitted to the Hong Kong Exchanges and Clearing Limited regarding movements in securities for China Shineway Pharmaceutical Group Limited. It details movements in authorized and issued shares, public float sufficiency confirmation, and confirms compliance with listing rules. The document is structured as a regulatory return form (FF301) and does not contain financial statements or management discussion. It is a regulatory compliance filing related to share capital and public float status, not a financial report or announcement of voting results. Therefore, it fits best under Regulatory Filings (RNS). The document length (7998 characters) and content confirm it is a substantive regulatory filing rather than a brief announcement or report publication notice.
2026-04-30 English
Notification Letter to Non-registered Shareholders - Notice of Publication of 2025 Annual Report, Circular, Notice of the Annual General Meeting, Proxy Form and Environmental, Social and Governance Re
Report Publication Announcement Classification · 95% confidence The document is a notification letter informing non-registered shareholders that the Company’s 2025 Annual Report, AGM circular/notice/proxy form, and 2025 ESG Report have been published online (on the Company’s and HKEX websites). It does not contain the reports themselves but simply announces their availability. Under the “Menu vs Meal” rule, this is a brief notice of report publication rather than the reports, fitting the Report Publication Announcement category.
2026-04-23 English
Notification Letter to Registered Shareholders - Notice of Publication of 2025 Annual Report, Circular, Notice of the Annual General Meeting , Proxy Form and Environmental, Social and Governance Repor
Report Publication Announcement Classification · 95% confidence The document is a notification letter informing shareholders that the Annual Report 2025, AGM circular and notice, proxy form, and the ESG Report 2025 are now available online. It does not include the reports themselves but announces their publication. This matches the definition of a Report Publication Announcement (RPA).
2026-04-23 English
ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2025
Environmental & Social Information Classification · 100% confidence The document is titled 'Environmental, Social and Governance Report 2025' and contains detailed information on the company's ESG initiatives, performance data, governance structure, environmental metrics, social responsibility activities, and sustainability policies. It references the reporting period as the year ended 31 December 2025 and follows ESG reporting codes and GRI standards. The content is comprehensive and includes quantitative data, policies, and governance details, consistent with an ESG report. There is no indication that this is an announcement or a brief summary; rather, it is the full ESG report itself. Therefore, the document fits the category of Environmental & Social Information (SR).
2026-04-23 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 90% confidence The document is a formal Notice of Annual General Meeting for China Shineway Pharmaceutical Group Limited, detailing the date, location, agenda items (ordinary resolutions), proxy instructions, and related meeting arrangements. This clearly matches the AGM Information category rather than a financial report, proxy statement, or voting results notice. Hence, it is classified as AGM Information (AGM-R).
2026-04-23 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.